Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2019

View Archived Issues

Rb and CDK

Food dye is secret ingredient for tissue-feeding vasculature

New engineered oncolytic vaccina virus constructs show cancer-specific activity

Phase III ASCEND study of Calquence meets primary endpoint at interim analysis

Long-term treatment for wet AMD using a single dose of OXB-203 shows promise

Positive interim data presented for first cohort in Polish phase I/II study of annamycin in AML

European Commission grants conditional approval for lorlatinib in patients with ALK-positive NSCLC

Study links KIAA1217 gene to cervical segmentation defects

Waylivra receives conditional marketing authorization from the European Commission

Humanized cells allow efficient flu virus isolation and growth

FDA clears IND application for NNI-362

Lentiviral CYBB gene therapy relieves disease symptoms in an X-CGD infant

Dupixent receives European approval for severe asthma

Ocular Therapeutix presents preliminary first-in-human data for OTX-TIC implant

First-in-human data presented for IVMED-10 and IVMED-20 for post-cataract inflammation

Pilot study of L1-79 demonstrates trends towards improvement in male subjects with ASD

Merck & Co. patents LRKK2-mutant inhibitors

Japanese researchers present IDO1 and/or TDO inhibitors

Enterprise Therapeutics discloses SCNN1A blockers

Jubilant Biosys describes new PADI4 inhibitors

JS Innopharm patents IDO1 and/or TDO inhibitors

Durect reports preliminary data from phase IIa study of DUR-928 in alcoholic hepatitis

REGENXBIO offers new interim phase I/IIa data on RGX-314 in wet AMD

MaxCyte advances phase I trial of MCY-M11 in advanced ovarian cancer and peritoneal mesothelioma

Phase II trial of Nepafenac Evolute shows postoperative pain reduction after cataract surgery

Allakos reports promising data from phase I study of AK-002 in severe allergic conjunctivitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...